This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look at REL-1017 ahead of the RELIANCE III results
Ticker(s): RLMDWho's the expert?
Institution: Yale University
- Assistant Professor at Yale School of Medicine and Assistant Director of the Yale Depression Research Program.
- Treats roughly 60 TRD patients per month, in a mix of settings including clinical practice and clinical trials; manages a growing ketamine service at Yale, which provides about 15-25 treatments per week.
- Served as PI or co-investigator on at least 12 clinical trials involving depression therapeutics including a large, federally funded trial comparing ECT and IV ketamine; runs a busy clinical service (the Yale Interventional Psychiatry Service), which offers electroconvulsive therapy, ketamine, and transcranial magnetic stimulation to patients.
Interview GoalDiscuss with a psychiatrist their opinion on REL-1017 as a monotherapy in treating MDD
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
